Use of amisulpride as an anti-emetic
View Patent ↗Amisulpride is used in the therapy of nausea, vomiting or retches. The therapy may utilize a novel injectable formulation, in unit dosage form, comprising less than 50 mg amisulpride.
1. A method for the prevention and/or treatment of nausea and vomiting that is induced by chemotherapy or radiation, wherein said method comprises administering amisulpride at a dose of 2.5 mg to 20 mg to a subject in need thereof.
2. The method according to claim 1 , wherein the subject is also administered an emetogenic agent.
3. The method according to claim 2 , wherein the emetogenic agent is a chemotherapeutic agent.
4. The method according to claim 2 , wherein the emetogenic agent is cisplatin.
5. The method according to claim 2 , wherein the emetogenic agent is an opiate.
6. The method according to claim 2 , wherein the emetogenic agent is morphine.
7. The method according to claim 1 , wherein the amisulpride is administered by intravenous injection.
8. The method according to claim 1 , wherein the amisulpride is administered by intramuscular injection.
9. The method according to claim 1 wherein the amisulpride is administered by subcutaneous injection.
10. The method according to claim 1 , wherein the amisulpride is administered by rectal administration.
11. The method according to claim 1 , wherein the amisulpride is administered by intranasal administration.
12. The method according to claim 1 , wherein the amisulpride is administered by buccal administration.
13. The method according to claim 1 , wherein the amisulpride is administered by oral, transdermal, sublingual or inhaled administration.
14. The method according to claim 1 , wherein the subject is a human.
15. The method according to claim 1 , wherein the amisulpride is in the form of an acceptable pharmaceutical salt.
16. The method according to claim 1 , wherein the amisulpride is administered in combination with another anti-emetic drug.
17. The method according to claim 16 , wherein the another anti-emetic drug is a 5HT3 antagonist.
18. The method according to claim 17 , wherein the 5HT3 antagonist is ondansetron.
19. The method according to claim 1 , wherein the amisulpride is administered by oral administration.
20. A method for the prevention and/or treatment of nausea and vomiting that is induced by chemotherapy or radiation, wherein said method comprises orally administering amisulpride at a dose of 2.5 mg to 20 mg to a subject in need thereof.